Terminated PHASE1 INTERVENTIONAL 1-arm NCT02192567

Open Label Study of DS-5573a

Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Advanced Solid Malignant Tumors

Interventions DS-5573a

Updated 8 times since 2017 Last updated: Mar 1, 2017 Started: Sep 30, 2014 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision

Other terminated trials from Daiichi Sankyo Co., Ltd.

More terminations from Daiichi Sankyo Co., Ltd.

Listed as NCT02192567, this PHASE1 trial focuses on Advanced Solid Malignant Tumors and remains terminated or withdrawn. Sponsored by Daiichi Sankyo Co., Ltd., it has been updated 8 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Mar 2024 — Jul 2024 [monthly]

Terminated PHASE1
Jan 2021 — Mar 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 3 earlier versions

Sep 2017 — Jun 2018 [monthly]

Terminated PHASE1
Mar 2017 — Sep 2017 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Jan 2017 — Mar 2017 [monthly]

Recruiting PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan